A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder
Latest Information Update: 03 Aug 2024
At a glance
- Drugs NBI-1070770 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Neurocrine Biosciences
Most Recent Events
- 01 Aug 2024 According to a Neurocrine Biosciences media release, top-Line data from this trial expected in 2025.
- 03 Apr 2024 According to a Neurocrine Biosciences media release, the first patient has been dosed in its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder.
- 26 Feb 2024 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT06267846).